Panmure Gordon restated their buy rating on shares of Scancell Holdings Plc (LON:SCLP) in a research note published on Friday. They currently have a GBX 68 ($0.89) price objective on the stock.

Shares of Scancell Holdings Plc (LON:SCLP) opened at 14.60 on Friday. The company’s 50-day moving average is GBX 18.11 and its 200 day moving average is GBX 17.47. Scancell Holdings Plc has a 1-year low of GBX 12.00 and a 1-year high of GBX 26.50. The company’s market cap is GBX 38.19 million.

About Scancell Holdings Plc

Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects.

Receive News & Ratings for Scancell Holdings Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell Holdings Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.